Request Samples

Patient Savings

Request a Rep

QULIPTA^® Resources

Download resources for your office and your patients

HCP Tools

QULIPTA Pharmacy Brochure

QULIPTA Pharmacy Flashcard

A QULIPTA guide for pharmacists with efficacy data as well as instructions for activating and processing the QULIPTA COMPLETE Savings Card.

DOWNLOAD

Downloadable templates to help your patients get started on QULIPTA

These are for informational purposes only and are not intended to provide reimbursement or legal advice. The information presented here does not guarantee payment or coverage.

QULIPTA Sample Appeals Letter

Sample Appeals Letter

Appeal a denied claim for QULIPTA.

DOWNLOAD

QULIPTA Letter of Medical Necessity Sample

Letter of Medical Necessity Sample

Establish the medical necessity of QULIPTA.

DOWNLOAD

QULIPTA Formulary Exception Letter

Formulary Exception Letter

Request a formulary exception to allow coverage for QULIPTA.

DOWNLOAD

Patient Resources

QULIPTA Patient Brochure

QULIPTA Patient Brochure (Coming soon)

A resource for patients you recently prescribed QULIPTA. You can take them through how QULIPTA works to prevent migraine and how they can save on QULIPTA.

DOWNLOAD

Learn about our QULIPTA savings offer.

LEARN MORE

INDICATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

WARNINGS AND PRECAUTIONS

Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

DRUG INTERACTIONS

Dose modifications are recommended when using the following:

Episodic migraine: Strong CYP3A4 inhibitors; CYP3A4 inducers; or OATP inhibitors
Chronic migraine: OATP inhibitors

In chronic migraine, avoid use with strong CYP3A4 inhibitors or with CYP3A4 inducers.

USE IN SPECIFIC POPULATIONS

Severe renal impairment or end-stage renal disease: In episodic migraine, 10 mg once daily. In chronic migraine, avoid use.

Avoid use in patients with severe hepatic impairment.

Dosage form and strengths: QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets.

US-QLP-230380

Please see full Prescribing Information.

This site is intended for U.S. healthcare professionals only.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

INDICATION AND IMPORTANT SAFETY INFORMATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

INDICATION

QULIPTA^® (atogepant) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.

WARNINGS AND PRECAUTIONS

Cases, including anaphylaxis, dyspnea, rash, pruritus, urticaria, and facial edema, have been reported with use of QULIPTA. Hypersensitivity reactions can occur days after administration. If a hypersensitivity reaction occurs, discontinue QULIPTA and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.

DRUG INTERACTIONS

Dose modifications are recommended when using the following:

Episodic migraine: Strong CYP3A4 inhibitors; CYP3A4 inducers; or OATP inhibitors
Chronic migraine: OATP inhibitors

In chronic migraine, avoid use with strong CYP3A4 inhibitors or with CYP3A4 inducers.

USE IN SPECIFIC POPULATIONS

Severe renal impairment or end-stage renal disease: In episodic migraine, 10 mg once daily. In chronic migraine, avoid use.

Avoid use in patients with severe hepatic impairment.

Dosage form and strengths: QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets.

US-QLP-230380